AXT expands preclinical imaging portfolio with addition of inviCRO’s innovative software platforms

AXT has recently bolstered their preclinical and translational imaging products portfolio with the addition of inviCRO’s innovative software platforms. These products empower users with increased visualisation and analytical capabilities as well as more efficient data and project management facilities.

inviCRO is a US-based company that specialises in providing translational imaging services and software for drug discovery and development efforts with applications ranging from tissue to human and from target identification to Phase 3 trials across the entire electromagnetic spectrum of imaging techniques.

Since 2009, they have completed more than 850 imaging trials for pharmaceutical groups, leveraging their internally developed software platforms. This demonstrated ability is the reason inviCRO’s software platforms are relied upon by more than 900 users in more than 175 laboratories across the world, including 70% of the top pharmaceutical companies. These labs use inviCRO’s systems to speed their R&D operations and therefore reduce the time it takes to bring treatments to market.

They offer two integrated software platforms:

  • VivoQuant™, a DICOM compliant post-processing suite for image data combining fundamental viewing functionality with powerful analysis capabilities. VivoQuant (“VQ”) supports data from most imaging modalities including MR, PET, SPECT, CT, FLECT, EM and Optical
  • iPACS®, a sophisticated web-based project management system designed for image study management applications. This platform allows for the efficient management, distribution, analysis and presentation of images and data associated with studies. iPACS offers a wide range of functionality for the organizational, processing, reporting and regulatory needs of preclinical and clinical imaging efforts.

"AXT supplies a wide variety of imaging systems that employ a variety of imaging technologies and modalities. These software platforms knit together our existing range and will help Australian medical researchers remain at the head of their field", said Richard Trett, Managing Director of AXT.

Bill Cupelo from inviCRO also commented:

We recognize Australia’s leading position in medical research, and we look forward to working with AXT and Australia’s world-class researchers to accelerate their work on drugs, treatments and therapies to fight complex diseases while leveraging our medical image informatics platform.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AXT Pty Ltd. (2019, June 19). AXT expands preclinical imaging portfolio with addition of inviCRO’s innovative software platforms. News-Medical. Retrieved on December 02, 2024 from https://www.news-medical.net/news/20160405/AXT-expands-preclinical-imaging-portfolio-with-addition-of-inviCROs-innovative-software-platforms.aspx.

  • MLA

    AXT Pty Ltd. "AXT expands preclinical imaging portfolio with addition of inviCRO’s innovative software platforms". News-Medical. 02 December 2024. <https://www.news-medical.net/news/20160405/AXT-expands-preclinical-imaging-portfolio-with-addition-of-inviCROs-innovative-software-platforms.aspx>.

  • Chicago

    AXT Pty Ltd. "AXT expands preclinical imaging portfolio with addition of inviCRO’s innovative software platforms". News-Medical. https://www.news-medical.net/news/20160405/AXT-expands-preclinical-imaging-portfolio-with-addition-of-inviCROs-innovative-software-platforms.aspx. (accessed December 02, 2024).

  • Harvard

    AXT Pty Ltd. 2019. AXT expands preclinical imaging portfolio with addition of inviCRO’s innovative software platforms. News-Medical, viewed 02 December 2024, https://www.news-medical.net/news/20160405/AXT-expands-preclinical-imaging-portfolio-with-addition-of-inviCROs-innovative-software-platforms.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AXT adds new range of microscopes suited to in situ incubator applications